PET, MRI study provides clues on Tourette Syndrome

11/21/2012 | Medscape (free registration)

Researchers using PET with carbon-11 flumazenil and structural MRI found that patients with Tourette Syndrome have lower binding of gamma-aminobutyric acid-ergic receptors in the ventral striatum, globus pallidus, thalamus, amygdala and right insula. The study findings are consistent with long-held theories about the disease concerning the disinhibition of particular circuits in the brain.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX